Melissa Tosca
Director Financiero/CFO en KIORA PHARMACEUTICALS, INC. .
Fortuna: 16 752 $ al 30/04/2024
Cargos activos de Melissa Tosca
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
KIORA PHARMACEUTICALS, INC. | Director Financiero/CFO | - | - |
Corporate Officer/Principal | 13/09/2022 | - |
Historial de carrera de Melissa Tosca
Antiguos cargos conocidos de Melissa Tosca.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Neomorph, Inc.
Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation. | Director Financiero/CFO | - | - |
Treasurer | - | - |
Formación de Melissa Tosca.
University of Arizona | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 4 |
Operativa
Director of Finance/CFO | 2 |
Corporate Officer/Principal | 1 |
Treasurer | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
KIORA PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Neomorph, Inc.
Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Melissa Tosca
- Experiencia